BCMU
NNVC icon

BlueCrest Capital Management (UK)’s NanoViricides NNVC Stock Holding History

BlueCrest Capital Management (UK)’s Portfolio NNVC Stock Details NNVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,920
Closed -$187K – 681
2014
Q1 		$187K Buy
+2,920
New +$250K 0.01% 467

Other funds holding NNVC

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CG
Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

BlueCrest Capital Management (UK)'s NNVC Position: Q2 2014 in Review

BlueCrest Capital Management (UK) sold out of NanoViricides (NNVC) in Q2 2014, closing a stake of 2,920 shares — an estimated $187K sold.

BlueCrest Capital Management (UK) first reported a position in NNVC in Q1 2014 and held it in 1 quarter. The position peaked at $187K in Q1 2014. 57 funds tracked by Wall St. Rank hold NNVC as of Q2 2014.

  • BlueCrest Capital Management (UK) reported no remaining NanoViricides position as of Q2 2014 after selling out during the quarter.
  • BlueCrest Capital Management (UK) sold 2,920 NanoViricides shares in Q2 2014, an estimated $187K.
  • BlueCrest Capital Management (UK) first reported a position in NanoViricides in Q1 2014 and held it in 1 quarter.
  • BlueCrest Capital Management (UK)'s NanoViricides position peaked at $187K in Q1 2014.
  • 57 funds tracked by Wall St. Rank held NanoViricides as of Q2 2014.

Based on BlueCrest Capital Management (UK)'s 13F filing for Q2 2014, filed 15 Aug 2014.